- Cantor Fitzgerald has initiated coverage on Clever Leaves Holdings Inc CLVR with an Overweight rating and a price target of $4.50.
- The stock offers better relative "pure-play" exposure to growth in overseas medical cannabis markets and eventually to recreational legalization in those markets, Cantor writes.
- According to the analyst Clever Leaves, a large-scale, low-cost producer of pharmaceutical-grade cannabis, could be among the world's top five cannabinoid exporters by the end of 2023.
- Also See: Clever Leaves To Ship First Export Of Cannabis To Israeli Partner InterCure.
- G-7 producers dominate end markets like Germany, but CLVR management expects to gain market share as more markets open to Colombian and Portuguese THC flowers.
- The company also benefits from several new distribution agreements, and its growth costs are sometimes one-tenth that of Canadian growers.
- With only $2 million in cannabinoid exports, there is a "show me" story for now. Cantor models CLVR cannabinoid sales of $27 million by 2023.
- The company has $27 million left in an equity facility that will be tapped in the months ahead. News flow about rec legalization in markets like Germany and Colombia may provide windows of opportunity for capital raises.
- Price Action: CLVR shares are up 3.26% at $0.95 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.